Since my initial blog article (The Little Pink Pill), the US Food and Drug Administration's (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 1 on June 18 that flibanserin, 100 mg (Girosa; Boehringer Ingelheim), was not significantly better than placebo for hypoactive sexual desire disorder (HSDD); they also voted unanimously that the benefits did not compensate for its adverse effects, which may include loss of consciousness and depression.Even before the advisory committee’s meeting debate was triggered whether this is a long sought step toward equality for women or is it the pharmaceutical industry’s fabrication of a questionable “disorder” (see below) in order to sell unnecessary and potentially dangerous drugs?
The disorder is Female Dysfunctional Syndrome (FDS) also called Hypoactive Sexual Desire Disorder (HSDD). It is a deficiency or absence of sexual fantasies and desire for sexual activity, as defined by the American Psychiatric Association (APA). The women are not averse to sex. They just they don’t care about it and stop thinking about it. They have problems with sexual desire, arousal, or orgasm and unexplained loss of sexual thoughts, fantasies and desire. They also have a low sex drive and a slow response to stimulation. Some complain of an inability to experience an orgasm. Researchers suggest that approximately 10% of women suffer from this disorder.Because the definition is vague and there are significant differences in sexual interest levels and in sexual functioning among women; the question is what is normal? Another question may be what led to this change? Many say that a decreased sex drive in a woman may be a normal part of aging, a dysfunctional relationship (i.e., an abusive partner), stress, a lack of exercise, diet or other medical problems.
Is this a real syndrome and if so does it need to be treated with medication? Many say that the pharmaceutical industry has played a central role in defining FSD/HSDD as an official psychiatric disorder and has exaggerated its scope by funding key research.
What do you think?
